MANNHEIM, Germany–(BUSINESS WIRE)–ERBA Diagnostics Mannheim GmbH, a global in vitro diagnostics company, today announced it has completed the acquisition of Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets. Financial terms were not disclosed.
The acquisition will see ERBA Diagnostics Mannheim add molecular diagnostics testing to its comprehensive suite of clinical testing products. ERBA Mannheim’s global network of direct sales and distribution, through its group companies in America, Europe, Russia, India and its knowledge of the emerging markets, will offer an excellent platform to Lumora to take its products for testing of hospital acquired infections, and HIV, respiratory disease, and other neglected diseases to a much larger market. Along with the specific diagnostic technologies, ERBA Diagnostics Mannheim will have the opportunity to further commercialise Lumora’s technologies such as BART and RapidMags. In addition, Lumora, has a number of ongoing commercial partnerships which will continue following the acquisition.